Business Context and Reporting Period
REGENXBIO Inc. (RGNX) filed a Form 8-K on March 6, 2024, reporting the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 4,565,260 shares of Common Stock at $23.00 per share and 1,521,740 pre-funded warrants at $22.9999 per warrant.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 913,050 additional shares.
- Expected Net Proceeds: Approximately $131.2 million (base case) or $150.9 million (if the over-allotment option is fully exercised), after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Barclays Capital Inc., and Stifel, Nicolaus & Company, Incorporated.
- Closing Date: Expected on March 11, 2024, subject to customary conditions.
Material Changes and Transaction Terms
This filing represents a material capital raise event. The pre-funded warrants have an exercise price of $0.0001 per share, are exercisable immediately, and do not expire. Holders of pre-funded warrants do not possess voting rights or other privileges of common stockholders until the warrants are exercised. The offering is conducted pursuant to an effective shelf registration statement on Form S-3.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, revenue outlook, or management commentary regarding operational performance. The primary risk disclosed relates to the dilution of existing shareholders resulting from the issuance of new shares and warrants. The underwriting agreement contains customary representations, warranties, and indemnification obligations.
Investor Verification Checklist
- Verify the final closing date and whether the underwriters exercised the 30-day over-allotment option.
- Confirm the actual net proceeds received after final deduction of offering expenses.
- Review the company's subsequent filings (e.g., 10-Q or 10-K) to assess the impact of this capital raise on cash liquidity and runway.
- Check for any changes in the company's capitalization table following the issuance of the pre-funded warrants.